anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGY RELEVANCE: Zanthoxylum bungeanum Maxim. (Z. bungeanum), a member of the Rutaceae family, has a rich history of traditional use in Asia for treating arthritis and toothache conditions. As characteristic chemical components, numerous kinds of alkaloids have been extracted from plants and their diverse biological activities have been reported. However, research on the isoquinoline alkaloid, a specific type of alkaloids, in Z. bungeanum was scarce.
AIM OF THE STUDY: The study aimed to isolate a novel isoquinoline alkaloid from Z. bungeanum and explore its pharmacological activity in vitro and analgesic activity in vivo.
MATERIALS AND METHODS: Isoquinoline alkaloid isolation and identification from Z. bungeanum were conducted using chromatographic and spectroscopic methods. The whole-cell patch-clamp technique was applied to assess its impact on neuronal excitability, and endogenous voltage-gated potassium (Kv) and sodium (Nav) currents in acutely isolated mouse small-diameter dorsal root ganglion (DRG) neurons. Its inhibitory impacts on channels were further validated with HEK293 cells stably expressing Nav1.7 and Nav1.8, and Chinese hamster ovary (CHO) cells transiently expressing Kv2.1. The formalin inflammatory pain model was utilized to evaluate the potential analgesic activity in vivo.
RESULTS: A novel isoquinoline alkaloid named HJ-69 (N-13-(3-methoxyprop-1-yl)rutaecarpine) was isolated and identified from Z. bungeanum for the first time. HJ-69 significantly suppressed the firing frequency and amplitudes of action potentials in DRG neurons. Consistently, it state-dependently inhibited endogenous Nav currents of DRG neurons, with half maximal inhibitory concentration (IC50) values of 13.06 ± 2.06 μM and 30.19 ± 2.07 μM for the inactivated and resting states, respectively. HJ-69 significantly suppressed potassium currents in DRG neurons, which notably inhibited the delayed rectifier potassium (IK) currents (IC50 = 6.95 ± 1.29 μM) and slightly affected the transient outward potassium (IA) currents (IC50 = 523.50 ± 39.16 μM). Furtherly, HJ-69 exhibited similar potencies on heterologously expressed Nav1.7, Nav1.8, and Kv2.1 channels, which correspondingly represent the main components in neurons. Notably, intraperitoneal administration of 30 mg/kg and 100 mg/kg HJ-69 significantly alleviated pain behaviors in the mouse inflammatory pain model induced by formalin.
CONCLUSION: The study concluded that HJ-69 is a novel and active isoquinoline alkaloid, and the inhibition of Nav and Kv channels contributes to its analgesic activity. HJ-69 may be a promising prototype for future analgesic drug discovery based on the isoquinoline alkaloid.
A wound closure apparatus and associated methods are provided which utilize blood fluid by activating the clotting cascade of blood fluid within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. An apparatus for providing ways of inhibiting anticoagulating agents and slowing fibrin clot degradation are also disclosed. Kits are also disclosed. The invention provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid. In further embodiments, the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.
The present invention relates to a magnetic medicinal microball for directionally breaking the back root of spinal nerve and a preparation method thereof. The magnetic medicinal microball is composed of magnetic materials, skeleton materials and a nerve damage agent and is prepared by the physical adsorption or the emulsification and cross linked embedment. After the magnetic medicinal microball is injected in a subarachnoid cavity, magnetic medicinal microballs are directionally aggregated at the back root of the spinal nerve under the guidance of an outer magnetic field; the medical microballs gradually release a target so as to damage the back root of the spinal nerve, namely the sensory nerve; the front root of the spinal nerve, namely the motor nerve is influenced, and other tissues are not influenced; consequently, the purpose of curing intractable pain and the pain of late cancers is achieved. The present invention has the advantages of economical and practical performance, low cost, simple clinical operation, no need of special instruments, easy and wide implementation, and little injury caused by clinical operation; the present invention is suitable for old people, weak people and patients to whom other analgesia therapy is not suitable for being carried out. The medicinal microballs can move under the guidance of the outer magnetic field; bilateral nerves and a plurality of paris of nerves can be damaged, so the therapeutic effect is more sufficient. On the basis of curing intractable pain, complicating diseases caused by the excessive diffusion of the existing nerve damage agent can be reduced. The present invention is a safe and effective nerve damage agent.
PURPOSE: A solid coloring material which is prepared using metal cation and plant extract and a cosmetic composition for makeup of skin or body surface are provided to suppress change of color with safety. CONSTITUTION: A method for producing a solid coloring material comprises: a step of reacting tannin or plant extract with salt of metal cation in aqueous solution to obtain complex with color; a step of reacting the complex with alkali metal silicate to obtain a product; and a step of precipitating the product in an aqueous medium. The complex with color is black and the metal cation is bivalent iron. The tannin is ellagic or garlic tannin. The plant is combretaceae. A cosmetic composition for makeup of skin or body surface contains the solid complex material. The cosmetic composition is used in the form of mascara, foundation, eye shadow, eye liner, or compact powder.
An inhaler for delivery of a medicament by inhalation is disclosed. The inhaler comprises a dose counting mechanism comprising a counter. The inhaler further comprises a dispensing mechanism, the dispensing mechanism being configured, on actuation, to dispense a dose of medicament and to adjust the counter. The inhaler further comprises a resetting member configured for movement in a first direction between a first position and a second position to reset the dispensing mechanism, and a prevention mechanism comprising a pair of first and second engaging members. If the movement of the resetting member in the first direction is reversed before it reaches the second position, the first and second engaging members prevent further actuation of the dispensing mechanism until the resetting member is again moved in the first direction. At least one of the first and second engaging members is configured to resiliently flex, under load, into abutment with a substantially rigid component of the inhaler. Preferably the dose counting mechanism counter indicates the number of remaining doses in, or the number of dispensed doses from, the inhaler.
Systems and methods for automatically recognizing and processing verbal data associated with medical treatment diagnosis and related billing, compliance and reporting procedures in the healthcare industry are provided. A method for completing and generating a claim form comprises providing an interactive voice interface for receiving and analyzing one or more verbal inputs to a computing system. The system interprets the one or more verbal inputs to fill one or more corresponding fields in an electronic form. The system continues to receive and analyze verbal inputs until the electronic form is completed. The system associates the content of the electronic form with one or more industry codes. The industry codes identify at least the nature of one or more services associated with the one or more verbal inputs. The system then arranges the codes in a predetermined manner to generate a claim for reimbursement that can be processed by a medical claims processing facility.
A collagen protein sponge of packed,is provided. The package transverse section is of lamellar structure. The collagen protein sponge is a sponginess thing which has functions of hematischesis and promoting raw surface to accrete, and is formed with high density collagen protein liquor in the condition of low temperature freezing, shows certain thickness lamellar; the package centre is provided with a layer collagen protein sponge arranged in a tray. The tray circumference shows upward vertical type of protruding edge, which can be also provided with 90 degrees hem. The tray centre is provided with the bottom groove shape corresponding to the collagen protein sponge shape. The upper, lower, and four sides of the collagen protein sponge are air. The upper, lower, and four sides of the trayis air, supreme and lowest lateral air layer are arranged with upper and lower container retes respectively. Circumference borderline of the upper and low container rete is sealed upper soliden inarched to constitute the thin and flat container bag. The production can be used for: intention, hematischesis, plastic surgery, and filling remnant cavity. Package structure of the production implements clean and safe collagen protein sponge, reliable package, is convenient to transport, storage and use.
The present invention relates to a medicine for treating burns and scalds, which belongs to a liquid preparation prepared by using the material Chinese herbal medicines of rhubarb, phellodendron bark, giant knotweed rhizome, Chinese holly, sanguisorba roots, etc. as main raw medicines to be soaked in alcohol solution. The medicine for treating burns and scalds has obvious effect on pain alleviation. Generally, pain can be alleviated within one minute after the medicine is applied. The medicine has strong infection resistance. Antibiotics are not required to be used after the medicine is applied. Burns and scalds can be treated by using an exposure method. The medicine has the advantages of convenient treatment, short treatment course and conspicuous curative effect, and is a Chinese medicament having no toxic or side effect. The medicine can be used for treating deep burns and scalds of an II degree and an III degree, and the burns and the scalds are caused by various chemical and physical substances.
This is a multicenter trial of the German Network Sepsis (SepNet) on patients with severe sepsis or septic shock. This study is supported by unrestricted grants.

The release of reactive oxygen species is an important factor in the development of sepsis induced multiorgan dysfunction syndrome. Common protection mechanisms are impaired in this syndrome. Serum levels of selenium, a cofactor of the glutathionperoxidase, are reduced. Several studies suggest a benefit of selenium application in patients with severe sepsis but data from large clinical trials are not available. After inclusion into the study, patients are randomly allocated to a placebo or selenium group. Treating physicians and patients are blinded regarding the allocation. The selenium group receives sodium selenite intravenously - 1000 µg as a bolus followed by a continuous infusion of 1000 µg per day until the end of ICU treatment but not longer than 21 days.

Procalcitonin (PCT) is a biomarker which is elevated in the blood of patients with severe sepsis/septic shock. Data from patients with community acquired pneumonia demonstrated that this biomarker can be used to decide on the duration of antimicrobial therapy. Studies with small sample size seem to confirm this in ICU patients with severe sepsis. However, this needs to be confirmed in a larger cohort. All patients are randomly allocated to a PCT guided algorithm or a control group. In the PCT-guided group, PCT is measured at randomization, day 4, 7, 10, and 14. Depending on the PCT course, the protocol recommends to change, alter, or stop anti-infectious measures. In the control group, anti-infectious therapy is left to the discretion of the treating physician.
The oximeters that will be evaluated are nonin co-pilot, massimo Radical 7, Philips (standard care), Innovo Premium iP900BP, nellcor PM1000N and USA medical supply Nano100. The sensors used will be reusable digital sensors for all oximeters. Oximeters will have been placed on patients' fingers (3 fingers on each hand) during an initial phase of clinical stability. Due to the impact of the fingers used for SpO2 measurement and bias that might be caused by right hand versus left hand, oximeters will be randomized to different fingers and hands for each patient. Measurements will be made when the SpO2 with the usual oximeter is \<97% as recommended and in the absence of changes of the respiratory parameters in the last 10 minutes. A set of measures that will include all the oximeters tested will be used. Once the oximeters are installed, at least 2 minutes will run out to let the oximeters reach steady state. Then when a standard of care blood gas is obtained, measurements will be taken simultaneously to the drawing of a standard care arterial blood gas by a clinician in the ICU. While the clinician takes the arterial blood gas, a picture will be simultaneously taken of the SpO2 readings shown by each oximeter, in addition to taking vital signs, O2 flow or FiO2.
Methods and compositions are provided for prophylaxis and treatment of breast cancer involving administration of a therapeutically effective amount of carbetocin and/or other long-acting oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin (carbetocin) and/or other long-acting oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit initiation or growth of breast cancer in the patient. The carbetocin and/or other long-acting oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient. Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a powder or aqueous formulation for intranasal delivery.
Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to the website composed of four topic areas (get active, eat well, stop smoking, and find support), receive a Fitbit and access to a Fitbit account and community group, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
PURPOSE: A selective infart-tissue-targeting bacteria and use thereof are provided to improve affinity and specificity to infarction myocardium or infarction brain, thereby reducing transfection other than heart. CONSTITUTION: A drug delivery system for infarcted tissues includes obligatory anaerobic or facultative anaerobic bacteria. The bactia are Salmonella, Clostridium, Bifidobacterium, E. coli, Yersinia enterocohtica, Listeria monocytogenies, Mycoplasma hominis, or Streptococcus. The bacteria are mutants which are deficient in ppGpp synthesis function. The bacteria comprise ppGpp for ppGpp synthesis, inactivated relA gene which codes synthetase or spoT gene. The infarction indicates either myocardial infarction or cerebral infarction. A pharmaceutical composition for treating the infarction comprises effective dose of drug delivery system and a pharmaceutically allowed carrier. The drug carrier includes the infarction treatment drug.
Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of losartan potassium and hydrochlorothiazide.

Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen (BUN) or serum creatinine were observed in 0.6 and 0.8 percent, respectively, of patients with essential hypertension treated with losartan potassium and hydrochlorothiazide alone. No patient discontinued taking losartan potassium and hydrochlorothiazide due to increased BUN. One patient discontinued taking losartan potassium and hydrochlorothiazide due to a minor increase in serum creatinine.

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.14 grams percent and 0.72 volume percent, respectively) occurred frequently in patients treated with losartan potassium and hydrochlorothiazide alone, but were rarely of clinical importance. No patients were discontinued due to anemia.

Liver Function Tests: Occasional elevations of liver enzymes and/or serum bilirubin have occurred. In patients with essential hypertension treated with losartan potassium and hydrochlorothiazide alone, no patients were discontinued due to these laboratory adverse experiences.

Serum Electrolytes: See PRECAUTIONS.
PROBLEM TO BE SOLVED: To obtain a skin cosmetic material excellent in improving skin quality such as the symptoms of senility and skin roughness by blending an α-hydroxy acid, a water-soluble polymer, the extract of mugwort, the cultured material of the spawn of Ganoderma lucidum at a specific ratio and setting pH of the material within a specific range. SOLUTION: This skin cosmetic material composition is obtained by blending (A) an α-hydroxy acid (3-12wt.%), (B) a water soluble polymer (0.1-5wt.%), (C) the extract of mugwort (0.001-5wt.%) and (D) the cultured material of the spawn of Ganoderm lucidum (0.001-5wt.%), and making its pH 3-7. As the α- hydroxy acid, an acid selected from among glycolic acid, lactic acid, tartaric acid and citric acid, is preferable. As the water soluble polymer, a polymer selected from among a xanthan gum, a guaran gum, a guar gum, a hydroxypropylmethylcellulose, alginic acid and a propylene glycol ester, is preferable. The extract of mugwort is obtained by extracting the raw or dried mugwort with water or an aqueous organic solvent. This skin cosmetic material can manifest a skin quality improving effect within a short period.
BACKGROUND: Biological sex influences the risk of depression and cognitive impairment, but its role in relation to postoperative delirium is unclear. This analysis investigates sex differences in delirium risk after coronary artery bypass graft (CABG) surgery and sex-related differences in relation to affective and cognitive symptoms.
METHODS: This is a secondary analysis of the Neuropsychiatric Outcomes After Heart Surgery (NOAHS) study, a single-site, observational study of a CABG surgery cohort (n = 149). Preoperative characteristics are stratified by sex, and baseline variables that differ by sex are evaluated to understand whether sex modifies their relationships with delirium. We also evaluate sex differences in one-month depression and cognition.
RESULTS: Female sex is associated with several delirium risk factors, including higher risk of preoperative depression and middle cerebral artery (MCA) stenosis. MCA stenosis was statistically associated with delirium only among women (OR 15.6, 95% CI 1.5, 164.4); mild cognitive impairment (MCI) was associated with delirium only in men (OR 4.6, 95% CI 1.2, 17.9). Other sex-based differences failed to reach statistical significance. Depression remained commoner among women 1 month post-CABG.
CONCLUSIONS: Women in this CABG cohort were more likely to have depression at baseline and 1 month postoperatively, as well as MCA stenosis and postoperative delirium. Sex might modify the relationship between post-CABG delirium and its risk factors including MCA stenosis and MCI. Cerebrovascular disease deserves study as a potential explanation linking female sex and a range of poor outcomes among women with coronary heart disease.
Safety and effectiveness in pediatric patients have not been established. Benzodiazepines are not recognized as a treatment for status epilepticus in neonates and should not be used in this population. 

SEIZALAM is not approved for use in neonates or infants. Serious adverse reactions including fatal reactions and the “gasping syndrome” occurred in premature neonates and low-birth-weight infants in the neonatal intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth-weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known (SEIZALAM contains 10 mg of benzyl alcohol per mL) [see Warnings and Precautions (5.10)].
Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
Provided herein are chimeric switch receptors (CSRs) comprising an ectodomain and/or transmembrane domain derived from an inhibitory receptor (e.g. PD1 or TGFbR2) fused to the transmembrane domain and/or intracellular signaling domain derived from one or more costimulatory proteins (e.g. CD2, CD28, MyD88, DAP10 or ICOS). The chimeric switch receptors are designed to convert a signal e.g. an inhibitory signal such as an immunosuppressive signal in the form of PD-L1 or TGFβ into a costimulatory signal. Also provided are engineered immune cells engineered to functionally express a chimeric switch receptor and/or a CAR and optionally also a chimeric cytokine receptor (CCR), and populations thereof, methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating e.g. cancer (e.g. solid or hematologic tumors) by administering the cells and the compositions.
This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.